FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964751644> ?p ?o ?g. }

• W2964751644 abstract "10610 Background: EGFR mutation is independently associated with a favorable response in NSCLC patients receiving EGFR-TKIs, regardless of gender or smoking history. However, recent reports have indicated that squamous cell carcinoma patients harboring EGFR mutations show a worse response to EGFR-TKIs than adenocarcinoma patients. We hypothesized that serum CYFRA21-1 is a predictive marker in EGFR mutated patients treated with EGFR-TKIs. Methods: We retrospectively screened 160 NSCLC patients harboring EGFR mutations (exon 19 deletions, L858R in exon 21, or other minor mutations) who received either gefitinib or erlotinib between 1992 and 2011. Patients were screened for histology, sex, age, smoking status, efficacy of EGFR-TKI and tumor markers (CEA/CYFRA21-1) at initial diagnosis. Results: Out of 160 eligible patients treated with EGFR-TKIs, 77 patients with high CYFRA21-1 level (>2 ng/ml) showed statistically shorter progression-free survival (PFS) than 83 patients with normal CYFRA21-1 level (median PFS 7.5 vs 14.0 months, p=0.006). No significant difference in PFS was observed between high CEA group (>5 ng/ml) and normal CEA group (median PFS 8.6 vs 11.2 months, p=0.2423). Multivariate analysis revealed that high CYFRA21-1 level is independently associated with PFS (HR 1.35; p=0.002) as well as squamous cell carcinoma (HR 1.40; p=0.020) and performance status 2-4 (HR 2.63; p=0.003). No statistically significant difference in overall survival (OS) was observed between high CYFRA21-1 group and normal group (median OS 24.8 vs 39.1 months, p=0.104). Conclusions: High CYFRA level patients have significantly shorter PFS, which may indicate that this subgroup has a larger squamous component and thus less response to EGFR-TKIs. Serum CYFRA21-1 level is a predictive marker of EGFR-TKIs efficacy and EGFR mutated patients can be divided into two subgroups according to CYFRA21-1 level at initial diagnosis." @default.
• W2964751644 created "2019-08-13" @default.
• W2964751644 creator A5000653374 @default.
• W2964751644 creator A5002327424 @default.
• W2964751644 creator A5016131935 @default.
• W2964751644 creator A5021107925 @default.
• W2964751644 creator A5022022857 @default.
• W2964751644 creator A5024943202 @default.
• W2964751644 creator A5031993878 @default.
• W2964751644 creator A5032826078 @default.
• W2964751644 creator A5036577393 @default.
• W2964751644 creator A5044227853 @default.
• W2964751644 creator A5058673085 @default.
• W2964751644 creator A5062454590 @default.
• W2964751644 creator A5072514763 @default.
• W2964751644 creator A5080938148 @default.
• W2964751644 creator A5090494204 @default.
• W2964751644 date "2012-05-20" @default.
• W2964751644 modified "2023-09-23" @default.
• W2964751644 title "Cytokeratin 19 fragment (CYFRA21-1) to predict the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) harboring EGFR mutation." @default.
• W2964751644 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.10610" @default.
• W2964751644 hasPublicationYear "2012" @default.
• W2964751644 type Work @default.
• W2964751644 sameAs 2964751644 @default.
• W2964751644 citedByCount "0" @default.
• W2964751644 crossrefType "journal-article" @default.
• W2964751644 hasAuthorship W2964751644A5000653374 @default.
• W2964751644 hasAuthorship W2964751644A5002327424 @default.
• W2964751644 hasAuthorship W2964751644A5016131935 @default.
• W2964751644 hasAuthorship W2964751644A5021107925 @default.
• W2964751644 hasAuthorship W2964751644A5022022857 @default.
• W2964751644 hasAuthorship W2964751644A5024943202 @default.
• W2964751644 hasAuthorship W2964751644A5031993878 @default.
• W2964751644 hasAuthorship W2964751644A5032826078 @default.
• W2964751644 hasAuthorship W2964751644A5036577393 @default.
• W2964751644 hasAuthorship W2964751644A5044227853 @default.
• W2964751644 hasAuthorship W2964751644A5058673085 @default.
• W2964751644 hasAuthorship W2964751644A5062454590 @default.
• W2964751644 hasAuthorship W2964751644A5072514763 @default.
• W2964751644 hasAuthorship W2964751644A5080938148 @default.
• W2964751644 hasAuthorship W2964751644A5090494204 @default.
• W2964751644 hasConcept C104317684 @default.
• W2964751644 hasConcept C121608353 @default.
• W2964751644 hasConcept C126322002 @default.
• W2964751644 hasConcept C143998085 @default.
• W2964751644 hasConcept C170493617 @default.
• W2964751644 hasConcept C204232928 @default.
• W2964751644 hasConcept C2776256026 @default.
• W2964751644 hasConcept C2777506169 @default.
• W2964751644 hasConcept C2777930144 @default.
• W2964751644 hasConcept C2778820342 @default.
• W2964751644 hasConcept C2779012181 @default.
• W2964751644 hasConcept C2779177807 @default.
• W2964751644 hasConcept C2779438470 @default.
• W2964751644 hasConcept C2780580887 @default.
• W2964751644 hasConcept C42362537 @default.
• W2964751644 hasConcept C501734568 @default.
• W2964751644 hasConcept C502942594 @default.
• W2964751644 hasConcept C54355233 @default.
• W2964751644 hasConcept C71924100 @default.
• W2964751644 hasConcept C81729549 @default.
• W2964751644 hasConcept C86803240 @default.
• W2964751644 hasConceptScore W2964751644C104317684 @default.
• W2964751644 hasConceptScore W2964751644C121608353 @default.
• W2964751644 hasConceptScore W2964751644C126322002 @default.
• W2964751644 hasConceptScore W2964751644C143998085 @default.
• W2964751644 hasConceptScore W2964751644C170493617 @default.
• W2964751644 hasConceptScore W2964751644C204232928 @default.
• W2964751644 hasConceptScore W2964751644C2776256026 @default.
• W2964751644 hasConceptScore W2964751644C2777506169 @default.
• W2964751644 hasConceptScore W2964751644C2777930144 @default.
• W2964751644 hasConceptScore W2964751644C2778820342 @default.
• W2964751644 hasConceptScore W2964751644C2779012181 @default.
• W2964751644 hasConceptScore W2964751644C2779177807 @default.
• W2964751644 hasConceptScore W2964751644C2779438470 @default.
• W2964751644 hasConceptScore W2964751644C2780580887 @default.
• W2964751644 hasConceptScore W2964751644C42362537 @default.
• W2964751644 hasConceptScore W2964751644C501734568 @default.
• W2964751644 hasConceptScore W2964751644C502942594 @default.
• W2964751644 hasConceptScore W2964751644C54355233 @default.
• W2964751644 hasConceptScore W2964751644C71924100 @default.
• W2964751644 hasConceptScore W2964751644C81729549 @default.
• W2964751644 hasConceptScore W2964751644C86803240 @default.
• W2964751644 hasLocation W29647516441 @default.
• W2964751644 hasOpenAccess W2964751644 @default.
• W2964751644 hasPrimaryLocation W29647516441 @default.
• W2964751644 hasRelatedWork W2017128352 @default.
• W2964751644 hasRelatedWork W2138939757 @default.
• W2964751644 hasRelatedWork W2164753308 @default.
• W2964751644 hasRelatedWork W2170669428 @default.
• W2964751644 hasRelatedWork W2214116879 @default.
• W2964751644 hasRelatedWork W2280520556 @default.
• W2964751644 hasRelatedWork W2283820188 @default.
• W2964751644 hasRelatedWork W2286164709 @default.
• W2964751644 hasRelatedWork W2407699272 @default.
• W2964751644 hasRelatedWork W2410464637 @default.
• W2964751644 hasRelatedWork W2596496013 @default.
• W2964751644 hasRelatedWork W2600355778 @default.
• W2964751644 hasRelatedWork W2767804305 @default.
• W2964751644 hasRelatedWork W2890048895 @default.

• next